Isomorphic Labs closes $5B Series C to push AI drug candidates to trials
Isomorphic Labs, the AI drug-discovery spinout from Google's DeepMind, has closed a $5 billion Series C funding round led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor alongside existing backers like GV, Capital G, Thrive Capital, and Temasek. The company says its AI-driven drug-design platform has shown positive preclinical results in oncology and immunology, and it has partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
GoKawiil's interpretation of the reporting above, not reported fact.
The massive raise, following a $2.1 billion round just months earlier, suggests investors see strong momentum behind AI-designed drug candidates as they near human testing, a critical and costly stage for any biotech venture. Bloomberg had reported the company was seeking a $50 billion valuation, which, if accurate, would mark a striking vote of confidence in AI's ability to accelerate pharmaceutical development. The timing also follows CEO Demis Hassabis stepping back from DeepMind leadership to focus on this venture, hinting at the strategic priority Alphabet and its backers may be placing on drug discovery.
- Isomorphic Labs raised $5B in Series C funding, co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz as a new investor.
- The company plans to use the funds to advance its AI drug-design engine toward clinical trials and expand into new medical areas.
- The raise follows a $2.1B Series B in May and comes amid reports the company sought a $50B valuation, though the final figure wasn't disclosed.
Source: techcrunch.com — Ram Iyer, 2026-11-17
Published there as: “Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.